论文部分内容阅读
目的:观察经动脉灌注化疗联合奥沙利铂+卡培他滨(XELOX)化疗方案治疗进展期胃癌的临床疗效和安全性。方法:选择进展期胃癌92例,随机分为观察组和对照组各46例。对照组采用标准XELOX化疗方案治疗,观察组采用经动脉灌注化疗联合标准XELOX化疗方案治疗,21天为1个周期。治疗2个周期后,比较两组近期和远期疗效,以及不良反应发生情况。结果:(1)观察组总有效率78.3%,非常显著高于对照组的47.8%(P<0.01);入组病例均至少完成3个化疗周期,对照组和观察组中位总生存时间分别为10.5个月和12.5个月,两组生存曲线比较,差异非常显著(P<0.01)。(2)两组不良反应发生率及毒性分级构成比比较,均差异不显著(P>0.05)。结论:经动脉灌注化疗联合XELOX化疗方案治疗进展期胃癌,近期疗效和远期疗效均优于单用XELOX化疗方案,且较安全。
Objective: To observe the clinical efficacy and safety of arterial infusion chemotherapy combined with oxaliplatin + capecitabine (XELOX) chemotherapy for advanced gastric cancer. Methods: 92 cases of advanced gastric cancer were selected and randomly divided into observation group and control group, 46 cases each. The control group was treated with standard XELOX chemotherapy. The observation group was treated with intra-arterial infusion chemotherapy combined with standard XELOX chemotherapy regimen for 21 days for one cycle. After two cycles of treatment, the two groups were compared for short-term and long-term efficacy, as well as the incidence of adverse reactions. Results: (1) The total effective rate in the observation group was 78.3%, which was significantly higher than that in the control group (47.8%, P <0.01). All the patients in the observation group completed at least 3 cycles of chemotherapy. The median overall survival time in the control group and the observation group were 10.5 months and 12.5 months, the difference between the two groups was significant (P <0.01). (2) There was no significant difference between the two groups in the incidence of adverse reactions and the constituent ratio of toxicity (P> 0.05). Conclusion: Arterial infusion chemotherapy combined with XELOX chemotherapy in the treatment of advanced gastric cancer, the short-term efficacy and long-term efficacy are superior to single XELOX chemotherapy, and more secure.